Cipla shares ratings cut by Morgan Stanley, CLSA on earnings
- Rs 20L seized from Ajit Chandila relative's home, another ex-cricketer held
- Indian American teen Eesha Khare invents wondrous 20-sec charger, Google eyes bid
- India and China ask SRs to work on more border steps
- Can't charge man with rape over consensual sex even if marriage eludes: Supreme Court
- Saudi Arabian authorities refuse to accept new Indian passports
Morgan Stanley and CLSA downgraded their ratings on Cipla Ltd shares a day after the Indian drugmaker reported a slower-than-expected rise in its October-December net profit.
Morgan Stanley cut its ratings to "equal-weight" from "overweight", citing slower growth prospects on the back of limited niche drug launches, lower margins and a higher tax rate. The bank also cut its price target to 414 rupees from 437 rupees.
CLSA cut its ratings on Cipla to "underperform" from "outperform", citing disappointing margins in the October-December quarter and expectations near-term earnings growth will be slower due a higher base. The bank cut its price target to 415 rupees from 475 rupees.
- 'Sophisticated' Indian cyberattacks targeted Pak military sites: Report
- Talkative Li quoted Weber, Hegel, Jobs, said PM is large-hearted
- Bihar food corp ends up with chaff as rice worth Rs 535 cr vanishes from mills
- In 7 lucrative minutes on May 9, Sreesanth bowled six balls, bookie made Rs 2.5 cr
- India and China ask border envoys to work on more steps
- Former Ranji player among 3 more held